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ABSTRACT
Introduction Dementia is a group of disabling disorders 
that can be devastating for persons living with it and for 
their families. Data- informed decision- making strategies 
to identify individuals at high risk of dementia are essential 
to facilitate large- scale prevention and early intervention. 
This population- based case–control study aims to develop 
and validate a clinical algorithm for predicting dementia 
diagnosis, based on the cognitive footprint in personal and 
medical history.
Methods and analysis We will use territory- wide 
electronic health records from the Clinical Data Analysis 
and Reporting System (CDARS) in Hong Kong between 
1 January 2001 and 31 December 2018. All individuals 
who were at least 65 years old by the end of 2018 
will be identified from CDARS. A random sample of 
control individuals who did not receive any diagnosis of 
dementia will be matched with those who did receive 
such a diagnosis by age, gender and index date with 1:1 
ratio. Exposure to potential protective/risk factors will 
be included in both conventional logistic regression and 
machine- learning models. Established risk factors of 
interest will include diabetes mellitus, midlife hypertension, 
midlife obesity, depression, head injuries and low 
education. Exploratory risk factors will include vascular 
disease, infectious disease and medication. The prediction 
accuracy of several state- of- the- art machine- learning 
algorithms will be compared.
Ethics and dissemination This study was approved 
by Institutional Review Board of The University of Hong 
Kong/Hospital Authority Hong Kong West Cluster (UW 
18-225). Patients’ records are anonymised to protect 
privacy. Study results will be disseminated through peer- 
reviewed publications. Codes of the resulted dementia 
risk prediction algorithm will be made publicly available 
at the website of the Tools to Inform Policy: Chinese 
Communities’ Action in Response to Dementia project 
(https://www. tip- card. hku. hk/).
INTRODUCTION
Dementia is a group of disabling disorders 
that can be devastating for persons living 
with it and their families. At present, it is esti-
mated that 50 million people globally have 
dementia, and the prevalence is expected 
to triple by 2050.1 To date, no cure has been 
found for any type of dementia.2 The WHO 
has identified developing effective preven-
tion strategies as a public health priority, and 
several predictive models have been devel-
oped over the past 10 years.3–6 The primary 
purpose of predictive algorithms such as a 
risk score is to identify individuals with high 
risk of dementia and to target corresponding 
preventive measures. Examining predictors 
generated by a predictive model can also 
deliver important information about modi-
fiable risk factors to the general public. As 
shown in a very recent UK study, effective 
intentions for potentially modifiable risk 
factors of dementia would save £1863 billion 
annually in England, reduce dementia prev-
alence by 8.5% and produce gains in quality- 
adjusted life year.7 In societies where the 
proportions of undiagnosed dementia are 
particularly high, risk- predictive algorithms 
Strengths and limitations of this study
 ► The study will employ population- representative 
longitudinal data retrieved from the Hong Kong 
territory- wide public healthcare system currently 
serving 7 million people. Findings are highly gener-
alisable to the Hong Kong population.
 ► Flexible machine- learning models will be adopted to 
use the size and depth of information in the dataset, 
which allows the generation of novel hypotheses.
 ► Since the predictive model is developed from real 
world data rather than research cohorts, it allows 
direct application of the derived algorithm for early 
identification of high- risk cases and early primary/
secondary intervention.
 ► Electronic health records like the Clinical Data 
Analysis and Reporting System inevitably lack 
details regarding certain risk factors (eg, socio-
economic status and lifestyle information), and 
information on underdiagnosed and misdiagnosed 
cases. Estimation of the effects of putative risk fac-
tors on dementia, and the predictive accuracy of the 
corresponding machine- learning model, may there-
fore be biased.
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may even serve as a valuable tool to support early diag-
nosis of dementia.
Established risk factors and predictive models for dementia
Substantial progress has been made in investigating the 
aetiology of dementia. Other than dominant risk factors 
that cannot be altered (such as age, family history and 
heredity),8 9 modifiable factors, such as less education, 
hypertension, hearing impairment, smoking, obesity, 
depression, physical inactivity, diabetes and low social 
contact have also been identified.10 11 The very recent 
2020 report of the Lancet Commission on dementia 
prevention, intervention and care added three more risk 
factors for dementia with newer, convincing evidence, 
including excessive alcohol consumption, traumatic brain 
injury and air pollution.12 In addition, many medications 
are shown to have either adverse (eg, anticholinergics) 
or protective effects (eg, statins, antihypertensive agents 
and non- steroidal anti- inflammatory drugs) on cogni-
tion.13–15 The Lancet 2020 report also recommended 
distinguishing medical conditions in midlife and late life 
as risk factors.12 It is worth noting that more population- 
based studies with longer observational periods are still 
needed to establish causal links.
Risk scores, a widely used tool for predicting disease 
risk, have been developed for many adverse health 
outcomes.16–18 The most highly cited dementia risk score 
was proposed by a Nordic team.6 Their score included 
only seven factors: age, education, sex, systolic blood 
pressure, body mass index, total cholesterol and physical 
activity. The authors recognised the model’s limitations 
and suggested that including more factors can improve 
prediction accuracy.
Choice of predictive models differs between research 
questions focusing on prediction and effect. Standard 
predictive models, represented by parametric models 
such as logistic regression and the Cox model, are typically 
interested in quantifying the effect of a predictor on the 
likelihood of developing dementia, while holding other 
relevant predictors constant.6 19 This approach tends to 
use a simplified linear depiction of reality and emphasises 
clinical interpretability. When prediction becomes the 
more valued goal, flexible machine- learning procedures, 
which have the ability to discover interaction, non- linear 
and higher- order effects, have the advantage of gener-
ating more accurate estimators of the likelihood.20 21 
A few studies have used machine learning for building 
predictive and diagnostic models of dementia at different 
stages using clinical records including imaging data.22–26 
A very recent study used unsupervised machine learning 
and successfully identified high likelihood of dementia 
in population- based surveys even without cognitive and 
behavioural measures.27
Life course approach and the cognitive footprint of dementia
In recent years, consensus has been growing that 
dementia is caused by complex interactions among 
genetic and environmental factors across the lifespan. 
Important theoretical models adopting this life course 
perspective are represented by cognitive reserve and cogni-
tive debts. Cognitive reserve theory suggests that ‘indi-
vidual differences in the cognitive processes or neural 
networks underlying task performance allow some 
people to cope better than others with brain damage’.28 
Educational attainment obtained early in life, occu-
pational complexity during the working lifetime and 
leisure activities in later life are among the factors shown 
to increase this reserve.29 30 In contrast, cognitive debt 
suggests that vulnerability to symptomatic Alzheimer’s 
disease accumulates through engagement in certain 
cognitive processes that actively deplete the cognitive 
reserve. Suggested cognitive debt factors include depres-
sion, anxiety, sleep disorder, neuroticism, life stress and 
post- traumatic stress disorder.31 Dementia might there-
fore be an outcome of a lifelong battle between reserve 
and debts.
Starting from the micronutrients and fat stores during 
fetal life to the management of health conditions in old 
age, exposure to risk factors at different stages of life 
may exert differential influence on the risk of dementia. 
Many life- course epidemiological studies have divided 
a person’s life into several periods. Identified ‘crit-
ical periods’ include the prenatal period, childhood to 
adolescence, adulthood, midlife, the transition period 
(young old) and old age.32 33 Adding a time dimension 
to the interaction between risk and protective factors may 
further complicate the picture.34
The cognitive footprint concept, drawing an analogy 
with the term ‘carbon footprint’ from the realm of envi-
ronmental science, was suggested in 2015.35 In line with 
the life course perspective, the basic idea is that a person’s 
cognition will be affected by a range of activities and 
events, that is, footprints, through the life course. Educa-
tion, infectious diseases, head injuries, exercise, drugs 
and toxicity can all have effects on cognition, including 
in later life. The cognitive footprint can either be nega-
tive as cognitive debts or positive as cognitive reserve. 
The original proposal of a cognitive footprint included 
consideration of the potential cognitive effects of medical 
and public health intervention and argued the possibility 
of modelling ‘a cognitive footprint of interventions and 
policies to meet the global challenges of dementia’. To 
date, this theory has not been comprehensively tested, 
although a recent study conducted in the UK adopted 
the term ‘cognitive footprint’ for psychiatric and neuro-
logical conditions and compared the prevalence of 
cognitive impairment in adults with a history of mood 
disorder, schizophrenia, multiple sclerosis and Parkin-
son’s disease.36
The cognitive footprint theory is theoretically plausible 
yet difficult to test, as it encompasses activities and events 
across the whole lifespan. In this project, we will develop 
and test a predictive algorithm of dementia based on the 
cognitive footprint theory by using a subset of the cogni-
tive footprint—the cognitive footprint of medical history.
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Electronic health records and machine-learning techniques
In recent years, digitally stored data have grown expo-
nentially, amassing extensive information on personal 
medical history and laboratory test results.37 Meanwhile, 
clinical big data analytics featured by machine- learning 
techniques are ever- evolving. However, electronic health 
records remain an underinvestigated source in terms of 
building predictive algorithms and addressing public 
health and clinical problems.
The public healthcare system in Hong Kong adopts 
electronic health records. The Clinical Data Analysis and 
Reporting System (CDARS) captures microlevel clin-
ical data including medical history of relevant dementia 
risk factors. Our preliminary analysis of CDARS inpatient 
data between 2001 and 2010 identified a total of 30 419 
patients with dementia diagnoses. Eighty per cent of these 
had one or more records before their first diagnosis of 
dementia, and more than 12% had more than 10 previous 
records available. In terms of comorbidities before or at 
the point of diagnosis of dementia, 40% patients had at 
least one diagnosis of unspecified essential hypertension, 
one- quarter had urethra and urinary tract disorders, 23% 
had cerebrovascular disease, and approximately one- fifth 
had pneumonia, diabetes and a history of falling. These 
initial results suggest that, although we cannot exhaust 
all possible factors to model the life- long cognitive foot-
print, a substantial number of factors can be measured or 
approximated.
Machine learning is a very broadly defined method 
that automates analytical model building. It covers any 
type of data- driven approach whose objective is learning 
from data, identifying patterns and making decisions 
with minimal human intervention. Newer methods from 
machine- learning literature, such as random forest and 
neural networks, have been introduced in medical studies 
for building predictive models.20 38 39 The conventional 
modelling approach has relied heavily on parametric 
methods with predetermined predictors. This contrasts 
with machine- learning models which have the ability 
to learn and generate new evidence by examining the 
complex structure of a large database of existing clin-
ical information. Considering the vast amount of clinical 
information in CDARS, machine learning is a valuable 
tool for deriving insights that can guide clinical decisions.
Combining the strength of the CDARS and modern 
machine- learning techniques, this study aims to develop 
and validate a dementia- predictive algorithm using 
machine learning. We hypothesise that the predictive 
and diagnostic accuracy of dementia can be significantly 
improved by applying super learning to a wider range 
of clinical records. Specifically, we aim to (1) identify 
important characteristics of patients (predictors) before 
their first diagnosis of dementia; (2) evaluate existing 
risk scores, developed from research cohorts, in terms 
of their predictive power of future dementia in a clinical 
population in Hong Kong; (3) test the theory of cognitive 
footprint by including relevant predictors from previous 
medical records and their interactions with the time 
dimension in the predictive model; and (4) develop a 
more flexible predictive model using machine- learning 
techniques to further improve the predictive accuracy 
of risk scores developed from conventional parametric 
models.
METHODS AND ANALYSIS
The study involves a descriptive analysis of the research 
cohort, a validation and benchmarking analysis of a stan-
dard predictive model using established risk factors, and 
an exploratory and validation analysis for developing the 
predictive algorithm using machine learning.
Data source and sample
The CDARS, a territory- wide database in Hong Kong, 
contains population- based electronic health records 
from the Hong Kong Hospital Authority. It is a decision 
supporting system for facilitating the retrieval of clinical 
data stored in multiple operation systems, including the 
Clinical Management System, for management deci-
sions, clinical audit, planning and research. The CDARS 
hosts comprehensive data on basic demographic, treat-
ment, diagnoses, prescriptions, laboratory test results 
and admission/discharge information that are entered 
by well- trained hospital staff. Data from the CDARS have 
been used in several earlier epidemiological studies on 
either the relationship between exposure and health 
outcomes or disease/medication trends and have proven 
to be reliable.40–43 This case–control study will be nested 
within the CDARS data from 2001 to 2018.
To protect patient privacy, patients’ records are pseudo- 
anonymised. Diagnoses are stored in CDARS through 
International Classification of Disease (ICD) codes. Many 
local studies validated the coding accuracy in CDARS and 
reported positive predictive values for different diseases 
ranging from 85.4% to 100%.41 44–46 A unique pseudo- 
identification number is generated for each patient to 
enable data linkage and retrieval for further analysis.
To date, CDARS holds more than 11 million patient 
records with clinical details from 1993 onwards.47 Our 
preliminary investigation of the data revealed that CDARS 
hosts 70 083 patient records with dementia diagnoses 
from 2001 to 2015, which is equivalent to an average of 
4672 dementia diagnoses per year. Ninety- six per cent of 
these patients received their diagnosis after the age of 65 
years. The headcount of dementia diagnosis by gender 
and age group is shown in table 1.
Case identification
A cohort of individuals who were at least 47 years of age 
at 1 January 2001, so that all included individuals will be 
at least 65 years old at the end of 2018, will be identified 
from CDARS. The inclusion criteria for the dementia 
group are: (1) the individual received the diagnosis of 
dementia when they were 65 years or older; (2) the diag-
nosis was made within the study period (1 January 2001 to 
31 December 2018). The date of first dementia diagnosis 
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will be defined as the index date. A random sample of 
control individuals who did not receive any diagnosis of 
dementia at any period (including the period before 1 
January 2001) will be matched with study cases by age, 
gender and index date with 1:1 ratio.48
Based on the average number of diagnoses obtained 
from 2001 to 2015, we expect the number of cases with a 
dementia diagnosis will be about 84 099. Assuming 80% 
statistical power at the 5% level of significance, our cohort 
will be able to detect an OR of 1.20 and 1.48, respectively, 
for conditions with 0.5% and 0.1% background rate.
Patient and public involvement
The abstract of the protocol is written in laymen’s term 
and a layman’s summary of project completion report 
will be published at the official website of the Research 
Grant Council (Hong Kong). The resulted dementia risk 
prediction algorithm and significant factors identified in 
the model will be made publicly available at the website 
of the Tools to Inform Policy: Chinese Communities’ 
Action in Response to Dementia project (https://www. 
tip- card. hku. hk/) to raise public awareness of risk factors 
of dementia.
Measures
Dependent variable
The dependent variable in this study is whether an indi-
vidual has received a diagnosis of dementia of any kind, 
including Alzheimer’s disease, vascular dementia, Lewy 
body dementia or other kinds of dementia. Individuals 
who have any diagnosis records of ICD-9- CM-290, 294.1, 
294.2, 331.0, 331.1, 331.82 in CDARS will be coded as 1; 
the matched controls will be coded as 0.
Our primary aim is to predict dementia of any kind. As 
a secondary objective, various types of dementia, repre-
sented by Alzheimer’s disease and vascular dementia, will 
also be investigated. Mild cognitive impairment (MCI) 
(ICD-331.83) is also considered to account for preclinical 
dementia. However, preliminary analysis of the 2001–
2010 inpatient data identified a zero record of MCI. 
Hence, the prevalence rate of MCI will likely be too low 
to generate any significant findings.
Risk factors: age period at exposure
All relevant medical conditions from 1993 onwards will 
be identified in CDARS. Age at exposure, approximated 
by the date of record, will be classified into three groups: 
21–45 for early adulthood, 46–64 for midlife, and 65 and 
above for old age. Except for education, childhood factors 
will not be considered in the current proposal since the 
study cohort needs to be at least 47 years old on 1 January 
2001 and information about their childhood and adoles-
cence is unlikely to have been accurately documented. All 
other factors will be broken down into more detailed cate-
gories based on exposure period. For example, diabetes 
will be recoded into three variables: diabetes diagnosed 
at early life (yes=1; no=0), diabetes diagnosed at midlife 
(yes=1; no=0) and diabetes diagnosed at late life (yes=1; 
no=0). The theoretical model—a cognitive footprint of 
medical history—is shown in figure 1.
Table 1 Number of dementia diagnoses* per year, stratified by gender and age group
Year
Female Male
<50 50–64 65+ Subtotal <50 50–64 65+ Subtotal
2001 12 71 4157 4240 23 117 2284 2424
2002 6 44 3160 3210 10 103 1846 1959
2003 5 32 1208 1245 8 66 791 865
2004 19 48 2627 2694 26 81 1452 1559
2005 15 71 2655 2741 15 84 1444 1543
2006 9 47 2506 2562 13 79 1340 1432
2007 15 59 2414 2488 20 94 1432 1546
2008 8 56 2613 2677 10 79 1452 1541
2009 6 71 3146 3223 9 96 1889 1994
2010 13 92 3389 3494 16 116 2113 2245
2011 5 105 3305 3415 11 123 1888 2022
2012 7 88 3170 3265 12 122 1896 2030
2013 10 68 3044 3122 13 103 1769 1885
2014 11 75 2477 2563 14 113 1594 1721
2015 1 90 2579 2670 8 92 1608 1708
Total 142 1017 42 450 43 609 208 1468 24 798 26 474
*Individuals who have any diagnosis records of ICD-9- CM-290, 294.1, 294.2, 331.0, 331.1, 331.82.
ICD, International Classification of Disease.
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Established risk factors
The risk factors in this study will be divided into two 
general groups: established risk factors and exploratory 
risk factors. The established factors include diabetes 
mellitus (ICD-9- CM 250),49 midlife hypertension (401),49 
midlife obesity (278), depression (296.2, 296.3, 300.4 and 
311),43 head injuries (800–804, 850–854 and 959.01)50 
and low education. In CDARS, educational level is 
recorded in five categories: less than primary, primary, 
secondary, tertiary education or above, and unknown. 
In this study, low education will be operationally defined 
as people who have less than primary or primary educa-
tion. Since collecting information on educational level 
is not mandatory, a considerable percentage of missing 
values will be expected. We will perform sensitivity anal-
yses using (1) a narrower definition of low education as 
people who have less than primary school education only 
and (2) the subsample of subjects with educational level 
information available to examine the robustness of the 
results. All these factors are measurable variables based 
on an influential review paper.2
Exploratory risk factors
Exploratory factors are selected based on the theory of 
cognitive footprint, which suggests that vascular disease, 
infectious disease, toxicity, nutrition and medication 
may all contribute significantly to the risk of dementia.35 
Infectious disease with ICD-9- CM codes from 001 to 139 
will be merged into 16 wider categories- intestinal infec-
tious diseases, tuberculosis, HIV and so on, according 
to the WHO classification. Toxicity includes poisoning 
by drugs, medicines and biological substances (ICD 
960–979), as well as toxic effects of substances of a 
mainly non- medicinal source (ICD 980–989). Nutri-
tion risk is measured by nutritional deficiencies (ICD 
260–269). We also include hearing loss (ICD 389) based 
on more recent evidence.10 51 Medication prescrip-
tion will be identified in CDARS by British National 
Formulary (BNF) chapters.52 Medication history of 
interest here is the prescription of antidepressants (BNF 
chapter 4.3), antipsychotics (4.2), lipid- regulating drugs 
including statins (2.12), and anti- hypertensive agents 
(2.5), diabetes medications (6.1) and polypharmacy. 
Polypharmacy is operationally defined as a medication 
count of five or more drugs.
All variables listed above are available in CDARS and 
can be retrieved electronically.42 43
Analytical plan
Data preparation and descriptive analysis
All data will be retrieved from the CDARS. Relevant vari-
ables for individuals with dementia diagnosis and their 
matched controls as listed in the Measures section will 
be retrieved for the identified cases. Comprehensive 
recoding processes will be carried out for all the risk 
factors. As missing values are presumably prevalent in the 
electronic health records, multiple imputations will be 
carried out using the MICE package in the open source 
software R.53 Sensitivity analysis will be conducted in the 
later phases to compare the results with and without 
imputation.
The sample will be divided into two subsamples: a 
training set and a testing set. In the training set, 70% of 
individuals will be randomly selected from the dementia 
group and 70% from the control group. The remaining 
subjects will be assigned to the testing set. The valida-
tion set approach is chosen instead of cross- validation 
due to the large sample size and complex structure of 
the data.
We will descriptively present the clinical profiles of 
patients with and without dementia.
Differences in terms of risk established and exploratory 
risk factors will be compared using Student’s t- test and 
χ2 test. Characteristics of patients with different types of 
dementia will be compared using analysis of variances.
Figure 1 The theoretical model—a cognitive footprint of personal and medical history.
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Benchmarking using established risk factors and multiple logistic 
regression model
Using the same simple technique adopted by several 
previous studies, a standard conditional logistic regres-
sion model will be fitted to the training sample using 
established risk factors only. We will use parameter esti-
mates estimated from the training sample to compute 
estimated probabilities of developing dementia for indi-
viduals in the test set. The area under the receiver oper-
ating characteristic curve (AUC) and the c- statistics for 
the test sample will be calculated to evaluate the sensi-
tivity and specificity.54
Developing the predictive algorithm using machine learning
This phase includes two steps. First, we will keep using 
the logistic regression model while adding exploratory 
risk factors based on the cognitive footprint of medical 
history. This step aims to examine the effect of explor-
atory predictors. Machine- learning techniques will be 
introduced in the next step.
Super learner
The concept of machine learning covers a broad range of 
algorithms. Given that there is rarely a single algorithm 
that universally outperforms others, it is often difficult 
to decide a specific machine- learning algorithm without 
adequate priori information about the data. In this 
project, a priori- specified ensembling machine- learning 
approach, super learning, will be implemented. Super 
learning combines multiple algorithms to a single algo-
rithm and returns the best predictive model based on 
cross- validated test mean square error (MSE). It has opti-
mality properties and was shown to be a powerful method 
in predicting mortality risk.20 Technical details regarding 
super learning are published elsewhere.55 56
Specifically, more than 10 algorithms will be imple-
mented in this super learning procedure, including 
generalised boosted regression, penalised regression, 
multivariate adaptive regression splines, random forest, 
support vector machine and neural network. The best 
algorithm will be selected based on the estimated MSE 
based on the 10- fold cross- validation. Estimation results 
obtained from the best algorithm will be applied to the 
testing set to predict group membership. Estimation 
outcomes, such as AUC values, sensitivity, specificity and 
c- statistics, obtained from conventional logistic models 
and machine- learning models will be compared and 
discussed. The SuperLearner package in R will be used 
to perform the machine- learning analysis.57 The open 
source statistical software R will be used for the data 
analysis.58
LIMITATIONS
The proposed study has some limitations. First, a health 
registry database like the CDARS inevitably lacks details 
regarding relevant risk factors (eg, prenatal, childhood, 
adolescent and other early- life risk factors, socioeconomic 
status and lifestyle information). Findings regarding the 
relative importance of predictors included may be biased 
due to insufficient control of other putative factors, and 
the predictive accuracy for dementia may be compro-
mised. Second, pieces of information on underdiagnosed 
and misdiagnosed cases are not available. Given the 
general undertreatment and underdiagnosis of dementia 
in Hong Kong and the possibility that mild cases of other 
conditions are managed in community outpatient clinics 
rather than public hospitals, the effects of risk factors on 
dementia may be overestimated as only severe cases were 
captured in electronic health records. Third, inference 
regarding the risk score or likelihood of dementia can 
only be made to clinical populations instead of the general 
population in Hong Kong. The effects of risk factors may 
therefore be underestimated since controls selected from 
this clinical population of people with complex medical 
needs are likely to carry a higher risk of dementia than 
the general population.59 Fourth, as we are unable to 
have access to scores of the cognitive assessments, and as 
it appears that most clinicians may not be coding MCI 
cases, we will likely be picking up dementia cases which 
are already of moderate severity, leading to biased esti-
mate of the effects and corresponding predictive accura-
cies generated from candidate machine- learning models. 
Despite these limitations, we believe it is important to 
evaluate the replicability of findings generated from 
research cohorts using real- life electronic health records. 
The purpose is to examine to what extent real- world 
diagnoses can predict dementia, irrespective of specula-
tions about factors influencing these diagnoses.60 Clinical 
algorithms and tools derived from real- life scenarios can 
be more easily translated and applied to assist clinical 
decision- making.
DATA STATEMENT
Patients’ records that will be used in this study are 
required by law to be safety stored for privacy reasons. 
All data collected for this study will be anonymised. A 
designated server will be used to store the data and the 
server will be secured in a locked rack cabinet. This server 
will be backed up by another server with a similar level of 
security and the data stored inside will be encrypted. Only 
principal investigator (HL) and her delegates will have 
access to the servers. Technical appendix, statistical code 
and a synthetic dataset will be made available at the Hong 
Kong University website.
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